IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer

Summary: Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has been documented. To study acquired resistance, we developed Olaparib-resistant (OlapR) cell lines through chroni...

Full description

Bibliographic Details
Main Authors: Amy R. Leslie, Shu Ning, Cameron M. Armstrong, Leandro S. D’Abronzo, Masuda Sharifi, Zachary A. Schaaf, Wei Lou, Chengfei Liu, Christopher P. Evans, Alan P. Lombard, Allen C. Gao
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:iScience
Subjects:
Cell biology
Cancer
Transcriptomics
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004224002050

Internet

http://www.sciencedirect.com/science/article/pii/S2589004224002050

Similar Items